MX2020013636A - Sales de (s)-(5-ciclobutoxi-2-metil-6-(1-(piperidin-4-il)-1h-piraz ol-4-il)-3,4-dihidroquinolin-1(2h)-il)(ciclopropil)metanona y formas solidas de las mismas. - Google Patents

Sales de (s)-(5-ciclobutoxi-2-metil-6-(1-(piperidin-4-il)-1h-piraz ol-4-il)-3,4-dihidroquinolin-1(2h)-il)(ciclopropil)metanona y formas solidas de las mismas.

Info

Publication number
MX2020013636A
MX2020013636A MX2020013636A MX2020013636A MX2020013636A MX 2020013636 A MX2020013636 A MX 2020013636A MX 2020013636 A MX2020013636 A MX 2020013636A MX 2020013636 A MX2020013636 A MX 2020013636A MX 2020013636 A MX2020013636 A MX 2020013636A
Authority
MX
Mexico
Prior art keywords
dihydroquinolin
cyclobutoxy
methanone
piperidin
cyclopropyl
Prior art date
Application number
MX2020013636A
Other languages
English (en)
Inventor
George P Luke
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of MX2020013636A publication Critical patent/MX2020013636A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención describe sales de (S)-(5-ciclobutoxi-2-metil -6-(1-(piperidin-4-il)-1H-pirazol-4-il)-3,4-dihidroquinolin-1(2H) -il)(ciclopropil)metanona, formas sólidas de las mismas y métodos para preparar y usar las mismas.
MX2020013636A 2018-06-29 2019-06-28 Sales de (s)-(5-ciclobutoxi-2-metil-6-(1-(piperidin-4-il)-1h-piraz ol-4-il)-3,4-dihidroquinolin-1(2h)-il)(ciclopropil)metanona y formas solidas de las mismas. MX2020013636A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862692546P 2018-06-29 2018-06-29
US201862692554P 2018-06-29 2018-06-29
PCT/US2019/039677 WO2020006329A1 (en) 2018-06-29 2019-06-28 Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereof

Publications (1)

Publication Number Publication Date
MX2020013636A true MX2020013636A (es) 2021-03-25

Family

ID=68984963

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013636A MX2020013636A (es) 2018-06-29 2019-06-28 Sales de (s)-(5-ciclobutoxi-2-metil-6-(1-(piperidin-4-il)-1h-piraz ol-4-il)-3,4-dihidroquinolin-1(2h)-il)(ciclopropil)metanona y formas solidas de las mismas.

Country Status (12)

Country Link
US (1) US20210261528A1 (es)
EP (1) EP3813835A4 (es)
JP (1) JP2021529764A (es)
KR (1) KR20210025615A (es)
CN (1) CN112584835A (es)
AU (1) AU2019293260A1 (es)
BR (1) BR112020026359A2 (es)
CA (1) CA3103153A1 (es)
IL (1) IL279673A (es)
MX (1) MX2020013636A (es)
SG (1) SG11202012787PA (es)
WO (1) WO2020006329A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021003163A1 (en) 2019-07-01 2021-01-07 Forma Therapeutics, Inc. Treating cancer with a bromodomain and extra-terminal (bet) family inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009315735B2 (en) * 2008-11-11 2013-01-10 Novartis Ag Salts of fingolimod
US20160256448A1 (en) * 2013-11-18 2016-09-08 Forma Therapeutics, Inc. Tetrahydroquinoline compositions as bet bromodomain inhibitors
TWI742513B (zh) * 2013-11-18 2021-10-11 美商弗瑪治療公司 作為bet溴域抑制劑之四氫喹啉組成物

Also Published As

Publication number Publication date
KR20210025615A (ko) 2021-03-09
US20210261528A1 (en) 2021-08-26
SG11202012787PA (en) 2021-01-28
CN112584835A (zh) 2021-03-30
EP3813835A4 (en) 2022-03-02
EP3813835A1 (en) 2021-05-05
CA3103153A1 (en) 2020-01-02
IL279673A (en) 2021-03-01
AU2019293260A1 (en) 2021-01-07
BR112020026359A2 (pt) 2021-03-30
JP2021529764A (ja) 2021-11-04
WO2020006329A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
MX2020011746A (es) Terapias genicas para los trastornos lisosomales.
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MX2019007021A (es) Anticuerpos il-11ra.
MX2023013342A (es) Celulas que expresan el receptor de antigeno quimerico (car) con funcion o expresion de tet reducida y metodos de uso de las mismas.
MX2020011745A (es) Terapias genicas para los trastornos lisosomales.
MX2019005076A (es) Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2.
MX2018001497A (es) Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
MX2020011748A (es) Terapias genicas para los trastornos lisosomales.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MY195442A (en) Anti-CD40 Antibodies and Their Uses
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
WO2015143188A8 (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
PH12019502171A1 (en) Composition and methods for immunooncology
MX2019011789A (es) 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
MX2018010971A (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
MX2019009485A (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
JOP20210305A1 (ar) صيغ إيماتينيب وتصنيعها واستخداماتها
MX2020013421A (es) Composiciones de dióxido de silicio de carbono poroso biogénico, métodos de elaboracion y uso de estas.
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
CR20220156A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
MX2021012250A (es) Formas solidas de (e)-3-[2-(2-tienil)vinil]-1h-pirazol.
MX2016006571A (es) Aparatos y metodos de seleccion de anticuerpo.
PH12016501689A1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof